J&J Buys Aragon, Boosting Prostate Cancer Franchise Beyond Zytiga
This article was originally published in The Pink Sheet Daily
Executive Summary
The buyout gives J&J Aragon’s androgen receptor inhibitor similar to Medivation’s Xtandi, a potential blockbuster and competitor. In the process, Aragon’s investors will back new spinout Seragon, created to house an estrogen receptor blocker.